Dan Ferry
Host, LifeSci Advisors
Replay available
Rain Enhancement Technologies Holdco, Inc. (RAIN) Q4 2022 Earnings Call
Rain Enhancement Technologies Holdco, Inc. (NASDAQ: RAIN) Q4 2022 earnings conference call, held 2023-03-09. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Avinash Phalanke
Chief Executive Officer, RAIN Oncology
Robert Doble
Chief Scientific Officer, RAIN Oncology
Richard Brice
Chief Medical Officer, RAIN Oncology
Nelson Kabatuan
SVP of Finance, RAIN Oncology
Michael Smith
Analyst, Guggenheim Partners
Joe Catanzaro
Analyst, Piper Sandler
Sumit Roy
Analyst, Jones Research
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Rain Enhancement Technologies Holdco, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.029 -- 00:00:05.073 Greetings and welcome to the RAIN Oncology Fourth Quarter and Full 00:00:05.073 -- 00:00:07.695 Year 2022 Earnings Score. 00:00:07.695 -- 00:00:12.178 At this time, all participants are in a listen-only mode. 00:00:12.178 -- 00:00:17.241 A brief question and answer session will follow the formal presentation. 00:00:17.241 -- 00:00:22.385 If anyone should require operator assistance during the conference, please press 00:00:22.385 -- 00:00:26.228 star zero on your telephone keypad. 00:00:26.228 -- 00:00:30.091 As a reminder, this conference is being recorded. 00:00:30.091 -- 00:00:36.355 It is now my pleasure to introduce your host, Dan Ferry of LifeSci Advisors. 00:00:36.355 -- 00:00:39.436 Thank you. You may begin. 00:00:39.577 -- 00:00:42.580 Thank you, operator, and good afternoon, everyone. 00:00:42.580 -- 00:00:47.963 With me today on the phone are Avinash Phalanke, Chief Executive Officer of RAINN Oncology, 00:00:47.963 -- 00:00:53.147 Robert Doble, Chief Scientific Officer, Richard Brice, Chief Medical 00:00:53.147 -- 00:00:58.590 Officer, and Nelson Kabatuan, SVP of Finance. 00:00:58.590 -- 00:01:03.536 During today's call, Avinash will provide an update on the broader strategic vision for 00:01:03.536 -- 00:01:08.977 the Mila Demetan franchise. Bob will review the biology and rationale of P53 00:01:08.977 -- 00:01:10.458 reactivation 00:01:10.458 -- 00:01:13.798 as it relates to our Mila Demetan clinical program. 00:01:13.798 -- 00:01:17.879 Richard will provide an update on RAIN's clinical strategy. 00:01:17.879 -- 00:01:21.440 And Nelson will review the financials. 00:01:21.480 -- 00:01:26.862 Before we begin, I'd like to remind you that statements made during this conference call 00:01:26.862 -- 00:01:31.225 that are no...